Compare Gilead Sciences, Inc. (GILD) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Mega Cap Growth ETF — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Vanguard Mega Cap Growth ETF trades at $94.42 (market cap $33.70B). The key difference: Gilead Sciences, Inc. is far larger — about 5.4× Vanguard Mega Cap Growth ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard Mega Cap Growth ETF for 45 Days on average.
| GILD | MGK | |
|---|---|---|
Market Cap | $182.40B | $33.70B |
Volume | 4,469,821 | 1,362,010 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $95.11 |
52-Week Low | $117.18 | $70.70 |
Typical Hold Time | 111 Days | 45 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
MGK, the Vanguard Morningstar Mega Cap Growth ETF, trades at $94.42, down 0.53% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides exposure to large-cap U.S. growth stocks like Nvidia and Apple, with a low expense ratio of 0.05% (Vanguard, 2026-07-18). Recent news highlights its strong five-year returns and suitability for long-term growth investors.
The outlook for MGK is positive, driven by its concentrated mega-cap growth holdings and cost efficiency, though risks include tech sector volatility and market concentration. Analyst sentiment is favorable, emphasizing its role in growth portfolios for investors seeking higher returns with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
